|
| Proteintech |
 |
|
 |
|
|
| |
Proteintech’s origins.
Proteintech Group was founded in 2002 by a group of scientists, who were actively engaged in NIH funded research at the time. One of the original founders and current CEO Dr. Jason Li was an Associate Professor of Immunology at the University of Illinois at Chicago during the company's foundation years. He says of the reasons behind Proteintech's establishment:
AT THE HEART OF OUR ASPIRATION WAS A COMPANY FOR SCIENTISTS BY SCIENTISTS; AN ANTIBODY PROVIDER THAT WOULD OFFER RESEARCHERS THE ADVANTAGE — NOT INVESTORS.
Part of Proteintech Group's early vision was to make all its own products, to the highest standards possible, and never source a single antibody from any other provider. This would offer researchers many advantages, including a way of avoiding the same antibodies sold under different brand names by different companies – an unregulated practice that has arisen within the industry.
With one hundred percent original products Proteintech offers its customers sincerity and integrity, qualities you will discover continually throughout this brochure. You can only buy Proteintech antibodies directly from Proteintech or via one of its approved distributors — when you receive your antibody and see the Proteintech logo on the vial, know that you hold something that is truly unique.
The Antibodies of Tomorrow…
Another fundamental part of the Proteintech Group vision was to produce an antibody for every single protein coded for in the human genome. Around the time of the company's inception the Human Genome Project was reaching its conclusion and the era of proteomics was dawning. Knowing that the study of proteins was key to translating the wealth of information contained within the genome, Proteintech set about providing the most vital tools for this task: antibodies — reagents without equal in the pursuit of protein research. Furthermore, the antibodies they aimed to provide were not just those relevant to the research of the day, but those of the discoveries of tomorrow. Because it is impossible to predict where science might go, and which targets may be in demand in future, comprehensive coverage of all human gene products is vital to supporting scientists. So far Proteintech has covered up to two-thirds of the human genome with its antibody products, and reaching the last protein in the genome is still an important target today.
The Whole-Protein Advantage
The benefits of whole-protein antibodies, among others, are their robustness and versatility. In addition to their capability at routine target detection – such as Western blotting for an abundant protein – they outperform peptide antibodies in exploratory science and in suboptimal conditions. For instance they show greater success in the analysis of patient samples where pathological proteins are present at endogenous levels or lower. Proteintech's anti-TDP-43 protein is a principal example of this…
Working with the Immune System
The lab employs a 102 day-long immunization protocol as standard, supplemented with booster immunizations to emulate a realistic immune response. This protocol, paired with the whole-protein approach, allows two major processes to happen in the host immune system that contribute to superior antibodies…
Validation
Study the schematic, which shows our validation hierarchy. You'll notice that they don't sell any antibodies that do not have a valid Western blot (WB). In exceptional circumstances they approve products for sale that have been reviewed by an independent medical pathologist for use in immunohistochemistry (IHC) without WB data. All validation experiments are performed using unmodified samples and endogenous levels of proteins.
Continuing Commitment and Support
The pursuit of their scientific ideals, their extensive validation procedures and the previous success stories of Proteintech antibody users, all attest to a scientific company that puts its customers and their research first.
Recently, Proteintech has pledged to undertake siRNA knockdown validation of most of its antibodies by the end of 2015. The specificities of over 550 of its antibodies have already been confirmed by customers using siRNA knockdown, and published in over 650 journal papers. In adding its own siRNA data to those previously available in the literature, Proteintech's aim is to make a gold standard of antibody validation more accessible to its customers. In doing so, Proteintech will be setting a new benchmark for antibody validation – one that crosses the boundary between provider and user, and absolves the question of with whom the responsibility of antibody validation should fall.
Proteintech is now committed to realizing this ambition, in addition to continuing its support of scientists beyond an antibody's arrival at the lab bench. At Proteintech they understand that the success stories of its antibodies only really start once they are in your hands, so they will go that extra mile to ensure that, in a discipline with so many variables, you have a trusted source of consistent, quality antibodies.
Defining Success
How do you define success? It is a question every company must explore from the outset. It characterizes a business' culture and approach to its customers. Essentially, it is a question that provides the framework for a company's operation and ethics. Success for Proteintech and its team isn't having 12,000 products in its catalog, nor is it seeing its sales increase. What really matters to Proteintech and the team here is the success of its antibodies in the hands of scientists – the people who make the discoveries that change and explain the world around us. They need well-validated antibodies they can really rely on, reagents they can trust to reveal true data. This is the axis about which Proteintech operates and prospers, valuing every item of peer-reviewed research published by its customers. It is the rapidly growing number of research papers featuring its antibodies that Proteintech counts as real, tangible success. With 10,000 publications and counting the numbers speak for themselves…
PRODUCTS – Categories:
>Polyclonal Antibodies
All Proteintech polyclonal antibodies are affinity purified and tested by indirect ELISA and Western Blot on unmodified lysates. 95% of Proteintech polyclonal antibodies are raised against whole proteins.
>Monoclonal Antibodies
Proteintech offers a broad monoclonal antibody product line. Each Proteintech monoclonal antibody has a unique manufactured in-house clone number. The high specificity with one epitope target makes their monoclonal antibodies very efficient, reflecting in less background staining and low cross-reactivity with other proteins. Also, high homogeneity of Proteintech monoclonal antibodies ensures minimal batch-to-batch variations, making the results easy to reproduce.
>Tag/Control Antibodies
The proteins that normally serve as internal controls in your research may not always take center stage, but they are indispensable for conducting meaningful research, most notably for the proper interpretation of Western blots. Loading control proteins and protein tags provide a reference to evaluate the changes in expression levels of target proteins and help to ensure that any increase or decrease in target protein levels is due to your experimental manipulations, and not due to errors in the Western blot procedure.
>Secondary Antibodies
Proteintech offers a comprehensive portfolio of secondary antibodies which have been validated in various applications including Western Blot, immunohistochemistry, immunofluorescence, ELISA, and flow cytometry.
>Recombinant Proteins
>Cytokines
>Growth Factors
>Fusion Proteins
Proteintech offers a wide range of high-quality fusion proteins. Their customer service provides fusion protein and peptide libraries, that can be used as a standard and a control in cell assay and immunoassay.
>ELISA Kits
Proteintech provides a wide range of two-site sandwich ELISA kits as ready-to-use and highly sensitive immunoassay kits.
>Custom Production
|
|
| Displaying 1 to 5 (of 9571 products) |
Result Pages: 1 |
|
|
|
|
